Fondazione Epatocentro Ticino

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Primary biliary cholangitis3 trials
• Fatty liver disease (MASLD/MASH)2 trials
• Liver cirrhosis1 trial

Phase

• Phase 32 trials
• Phase 21 trial

Status

• Active, not recruiting2 trials
• Recruiting2 trials
• Completed1 trial

Lead sponsor

• Fondazione Epatocentro Ticino2 trials
• Calliditas Therapeutics Suisse SA1 trial
• Ipsen1 trial
• Madrigal Pharmaceuticals, Inc.1 trial

Running trials

• Recruiting

  Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease

  NCT07051863· Fondazione Epatocentro Ticino· Source

  Contact: Andreas Cerny, Prof. Dr. med

• Active, not recruiting

  Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

  NCT04526665· Phase 3· Ipsen· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

  NCT03900429· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Recruiting

  Swiss Primary Biliary Cholangitis Cohort Study

  NCT03146910· Fondazione Epatocentro Ticino· Source

  Contact: Andreas Cerny, Prof. Dr. med

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Primary biliary cholangitis1 recruiting

Closed trials

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source